<DOC>
	<DOCNO>NCT00852397</DOCNO>
	<brief_summary>The purpose study ass bleed safety ( composite endpoint major clinically relevant non-major bleeding ) 2 dos apixaban ( 2.5 mg BID 5.0 mg BID ) placebo combination standard therapy ( aspirin /or additional antiplatelet therapy ) 24 week treatment period select subject recent ( ≤7 day ) acute coronary syndrome .</brief_summary>
	<brief_title>A Study Evaluate Safety Apixaban Acute Coronary Syndrome ( ACS ) Japanese Patients</brief_title>
	<detailed_description>Due withdraw global phase 3 study ( APPRAISE-2 ) safety issue , B0661004 Data monitoring committee ( DMC ) also recommend terminate study . Therefore , Pfizer decide stop study .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Acute Coronary Syndrome</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<criteria>Recent ( ≤ 7 day ) ACS Clinically stable , receive standard treatment ( patient must treat aspirin ≤ 100 mg/day , without clopidogrel 75 mg/day ticlopidine 200 mg/day ) base physician 's judgment ) Scheduled/planned cardiac catheterization , PCI , CABG invasive procedure plan 24 week ( within treatment period ) follow randomization Persistent severe hypertension , define systolic blood pressure ≥180 mm Hg diastolic pressure ≥110 mm Hg Active bleeding high risk bleeding ( e.g. , cirrhosis liver , history intracranial hemorrhage ) .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
</DOC>